Geron マネジメント

マネジメント基準チェック /34

Geronの CEO はChip Scarlettで、 Sep2011年に任命され、の在任期間は 13.17年です。の年間総報酬は$ 4.92Mで、 16%給与と84%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.021%を直接所有しており、その価値は$ 508.79K 。経営陣と取締役会の平均在任期間はそれぞれ2.6年と8.9年です。

主要情報

Chip Scarlett

最高経営責任者

US$4.9m

報酬総額

CEO給与比率	16.0%
CEO在任期間	13.2yrs
CEOの所有権	0.02%
経営陣の平均在職期間	2.6yrs
取締役会の平均在任期間	8.9yrs

経営陣の近況

Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

May 03

Recent updates

Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

May 03

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Mar 15

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Mar 05

Is Geron (NASDAQ:GERN) A Risky Investment?

Aug 25

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

May 12

An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Dec 20

Geron: A Major Catalyst For Shareholders Arrives In January - At Last

Sep 16

Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?

Sep 14

Geron rises on narrower-than-expected Q2 loss

Aug 12

Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt

Aug 05

Geron: Waiting For Godot

Jul 15

CEO報酬分析

Geron の収益と比較して、Chip Scarlett の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$201m
Jun 30 2024	n/a	n/a	-US$220m
Mar 31 2024	n/a	n/a	-US$201m
Dec 31 2023	US$5m	US$787k	-US$184m
Sep 30 2023	n/a	n/a	-US$175m
Jun 30 2023	n/a	n/a	-US$171m
Mar 31 2023	n/a	n/a	-US$150m
Dec 31 2022	US$3m	US$761k	-US$142m
Sep 30 2022	n/a	n/a	-US$131m
Jun 30 2022	n/a	n/a	-US$117m
Mar 31 2022	n/a	n/a	-US$118m
Dec 31 2021	US$2m	US$736k	-US$116m
Sep 30 2021	n/a	n/a	-US$108m
Jun 30 2021	n/a	n/a	-US$101m
Mar 31 2021	n/a	n/a	-US$87m
Dec 31 2020	US$2m	US$714k	-US$76m
Sep 30 2020	n/a	n/a	-US$81m
Jun 30 2020	n/a	n/a	-US$76m
Mar 31 2020	n/a	n/a	-US$75m
Dec 31 2019	US$2m	US$690k	-US$69m
Sep 30 2019	n/a	n/a	-US$47m
Jun 30 2019	n/a	n/a	-US$37m
Mar 31 2019	n/a	n/a	-US$30m
Dec 31 2018	US$3m	US$667k	-US$27m
Sep 30 2018	n/a	n/a	-US$27m
Jun 30 2018	n/a	n/a	-US$28m
Mar 31 2018	n/a	n/a	-US$28m
Dec 31 2017	US$3m	US$644k	-US$28m

報酬と市場: Chipの総報酬 ($USD 4.92M ) は、 US市場 ($USD 6.56M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Chipの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Chip Scarlett (73 yo)

13.2yrs

在職期間

US$4,924,092

報酬

Dr. John A. Scarlett, also known as Chip, M.D., has been the Chief Executive Officer of Geron Corporation since joining in September 2011 and has been its President since January 5, 2012. Dr. Scarlett is C...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
John Scarlett	Chairman of the Board	13.2yrs	US$4.92m	0.021% $ 508.8k
Michelle Robertson	Executive VP	1.2yrs	US$2.47m	0% $ 0
Andrew Grethlein	Executive VP & COO	5.8yrs	US$2.42m	0.00038% $ 9.3k
Scott Samuels	Executive VP	1.3yrs	US$3.61m	0% $ 0
Aron Feingold	Vice President of Investor Relations & Corporate Communications	no data	データなし	データなし
Shannon Odam	Senior VP & Chief People Officer	5.4yrs	データなし	データなし
Melissa A. Behrs	Executive VP of Business Operations & Chief Alliance Officer	17.8yrs	US$1.15m	データなし
Edward Koval	Executive VP & Chief Business Officer	2.9yrs	データなし	データなし
Faye Feller	Executive VP & Chief Medical Officer	2.3yrs	データなし	データなし
James Ziegler	Executive VP & Chief Commercial Officer	less than a year	データなし	データなし
Joseph Eid	Executive Vice President	no data	データなし	データなし

2.6yrs

平均在職期間

58.5yo

平均年齢

経験豊富な経営陣: GERNの経営陣は経験豊富であると考えられます ( 2.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
John Scarlett	Chairman of the Board	13.2yrs	US$4.92m	0.021% $ 508.8k
Gaurav Aggarwal	Independent Director	less than a year	US$290.82k	0% $ 0
V. Lawlis	Independent Director	12.7yrs	US$360.90k	データなし
Elizabeth O'Farrell	Lead Independent Director	5.7yrs	US$375.53k	0.0056% $ 136.8k
Robert Jay Spiegel	Independent Director	14.5yrs	US$350.90k	0.028% $ 692.6k
Susan Molineaux	Independent Director	12.2yrs	US$345.90k	0.022% $ 531.2k
John McDonald	Independent Director	2.2yrs	US$348.40k	0% $ 0
Dawn Bir	Independent Director	5.7yrs	US$343.12k	0% $ 0

8.9yrs

平均在職期間

66.5yo

平均年齢

経験豊富なボード: GERNの取締役会は経験豊富であると考えられます ( 8.9年の平均在任期間)。

Geron マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Geron Corporation Appoints Joseph Eid as Executive Vice President, Research and Development

Geron Corporation Announces Chief Commercial Officer to Depart, Effective August 31, 2024

Executive VP & COO notifies of intention to sell stock

Chairman of the Board notifies of intention to sell stock

Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

Geron Corporation, Annual General Meeting, May 09, 2024

Recent updates

Consensus revenue estimates increase by 55%

Geron Corporation Appoints Joseph Eid as Executive Vice President, Research and Development

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron: A Post Earnings And Funding Announcement Assessment

Geron Corporation Announces New Data to Be Present at Upcoming ASH Annual Meeting Highlighting Potential of RYTELO (Imetelstat) in Myeloid Hematologic Malignancies

Is Geron (NASDAQ:GERN) Using Too Much Debt?

Geron Corporation to Report Q3, 2024 Results on Nov 07, 2024

Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition

Geron Corporation Announces Chief Commercial Officer to Depart, Effective August 31, 2024

Geron Corporation to Report Q2, 2024 Results on Aug 08, 2024

Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?

Executive VP & COO notifies of intention to sell stock

Chairman of the Board notifies of intention to sell stock

Geron: Innovative Rytelo Enters A Challenging MDS Market

Geron Corporation Announces FDA Approval of RYTELO (imetelstat) for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron Corporation to Report Q1, 2024 Results on May 02, 2024

Consensus revenue estimates decrease by 16%

Geron Corporation, Annual General Meeting, May 09, 2024

Geron Corporation has completed a Follow-on Equity Offering in the amount of $149.999995 million.

Price target increased by 7.0% to US$5.08

Consensus revenue estimates decrease by 13%

New major risk - Share price stability

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Geron Corporation Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Consensus revenue estimates decrease by 21%, EPS upgraded

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q4, 2023 Results on Feb 28, 2024

New minor risk - Share price stability

Forecast to breakeven in 2026

Geron Announces 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron Announces Publication in the Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Consensus revenue estimates increase by 76%

Geron Corporation has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Geron Corporation to Report Q3, 2023 Results on Nov 02, 2023

Geron Corporation Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Is Geron (NASDAQ:GERN) A Risky Investment?

Geron Corporation Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

Consensus revenue estimates fall by 14%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Geron Corporation to Report Q2, 2023 Results on Aug 03, 2023

Geron Corporation Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

Geron Corporation Announces Submission of New Drug Application to FDA for First-In-Class Telomerase Inhibitor Imetelstat

Geron Corporation Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

Geron Corporation Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Consensus revenue estimates increase by 29%

Geron Corporation Announces Board Changes

Consensus revenue estimates decrease by 48%, EPS upgraded

Geron Corporation Announces Five Abstracts Related to Imetelstat Accepts at European Hematology Association Annual Meeting

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Chairman of the Board notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

Price target increased to US$4.50

An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Geron Corporation Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

Insufficient new directors

マネジメント基準チェック /34